AbbVie has secured global rights to IGI Therapeutics’ early-stage trispecific antibody, ISB-2001, targeting BCMA, CD38, and CD3 for multiple myeloma treatment. The $700 million upfront deal could reach $1.9 billion with milestones and royalties, covering key markets including North America, Europe, Japan, and China. ISB-2001 has orphan drug and fast track designations, with promising Phase 1 data showing a 79% response rate in heavily pretreated patients. AbbVie plans to explore applications beyond oncology, such as autoimmune diseases, reflecting growing interest in multifunctional antibody therapies.